Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZZ1 | ISIN: US07160F4046 | Ticker-Symbol:
NASDAQ
15.11.23
20:43 Uhr
0,184 US-Dollar
-0,002
-1,24 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BAUDAX BIO INC Chart 1 Jahr
5-Tage-Chart
BAUDAX BIO INC 5-Tage-Chart

Aktuelle News zur BAUDAX BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.02.Baudax Bio, Inc. - 8-K, Current Report2
15.02.NSE - Baudax Bio, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities2
13.02.Delisting of Securities of Sono Group N.V.; Baudax Bio, Inc.; Comera Life Sciences Holdings, Inc.; Missfresh Limited; Rose Hill Acquisition Corporation; Axcella Health; Zivo Bioscience, Inc.; Sonic Foundry, Inc.; Mobiquity Technologies, Inc. and others284NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common shares of Sono Group N.V. Sono Group N.V.'s securities were suspended on July 21, 2023...
► Artikel lesen
13.12.23Baudax Bio, Inc. - 8-K, Current Report4
20.11.23Baudax Bio, Inc. - 10-Q, Quarterly Report1
15.11.23Baudax Bio, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB4
15.11.23Baudax Bio, Inc. - 8-K, Current Report2
03.11.23Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview2
25.10.23Baudax Bio, Inc. - 8-K, Current Report4
13.10.23Baudax Bio, Inc. - 8-K, Current Report3
06.10.23Baudax Bio, Inc. - 8-K, Current Report1
02.10.23Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag3
23.08.23Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock262MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing...
► Artikel lesen
16.08.23Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update231Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio...
► Artikel lesen
30.06.23Baudax Bio Acquires TeraImmune, Inc.408TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of...
► Artikel lesen
12.05.23Baudax Bio, Inc.: Baudax Bio Reports First Quarter Financial Results and Provides Business Update1.092Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio...
► Artikel lesen
01.05.23Baudax Bio, Inc.: Baudax Bio Announces Closing of $4 Million Public Offering194MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings...
► Artikel lesen
27.04.23Baudax Bio, Inc.: Baudax Bio Announces Pricing of $4 Million Public Offering 255MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1